James Faulkner comments on the market implications of the Patient Capital Review. He then discusses knowledge-intensive companies in Vala’s portfolio and its selection process. Faulkner stresses Vala’s commitment to mentoring and helping investee companies through to exit. He also signals the need for greater digitisation of the administrative process of EIS investing.